Key result
Higher initial-dose lignocaine maintains continuous therapeutic levels in acute MI, with longer half-life in surgical patients.
Why the study?
Optimal lignocaine infusion regimens for achieving therapeutic plasma concentrations in patients with acute myocardial infarction and those with circulatory and hepatic dysfunction were unclear.
Does a higher initial dose regimen of lignocaine achieve continuous therapeutic levels faster than a lower dose regimen in patients with acute myocardial infarction?
Does a higher initial dose regimen of lignocaine achieve continuous therapeutic levels faster than a lower dose regimen in patients with acute myocardial infarction?
p-value: p=<0.02
A higher initial infusion rate of lignocaine is recommended to rapidly achieve therapeutic levels in AMI patients without circulatory impairment.
Higher-dose lignocaine infusion achieved continuous therapeutic levels in AMI; leaves open optimal regimen for dysrhythmia suppression.
Plasma lignocaine concentrations were measured during and after lignocaine infusions administered for suppressing ventricular dysrhythmias. Twenty-four patients with a primary diagnosis of acute myocardial infarction without gross circulatory disturbance received, after a bolus of lignocaine, either 4 mg/min for 30 minutes, 2 mg/min for two hours, then 1 mg/min thereafter or 1 mg/min throughout. The higher dose regimen produced continous therapeutic levels of lignocaine, which were achieved only after four hours by the lower dose. On the other hand, in patients who had undergone cardiac surgery and who had circulatory and heptic dysfunction the lower dose regimen achieved therapeutic levels early. The plasma half life was longer in the surgical group (P less than 0.02). The higher initial infusion rate is recommended for patients with acute myocardial infarction without gross circulatory impairment.
No takes yet. Share an insight, caveat, or question.
Aps et al. (1976) studied Acute myocardial infarction and ventricular dysrhythmias (n=24). Lignocaine vs. Bolus followed by 1 mg/min throughout was evaluated on Achievement of continuous therapeutic levels of lignocaine and plasma half-life (p=<0.02). A higher initial dose regimen of lignocaine produced continuous therapeutic levels in patients with acute myocardial infarction, while plasma half-life was longer in surgical patients (P<0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: